ICU Medical (NASDAQ:ICUI) Rating Reiterated by Needham & Company LLC

ICU Medical (NASDAQ:ICUI)‘s stock had its “hold” rating restated by stock analysts at Needham & Company LLC in a research report issued to clients and investors on Thursday, Benzinga reports.

A number of other equities research analysts have also issued reports on the stock. Raymond James increased their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Thursday, September 12th. Finally, KeyCorp increased their price objective on shares of ICU Medical from $136.00 to $147.00 and gave the company an “overweight” rating in a report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $149.00.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $178.72 on Thursday. The firm’s 50 day moving average price is $165.37 and its 200-day moving average price is $129.42. ICU Medical has a twelve month low of $78.28 and a twelve month high of $188.53. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76. The stock has a market capitalization of $4.35 billion, a PE ratio of -72.95 and a beta of 0.66.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.56. The company had revenue of $596.50 million during the quarter, compared to analyst estimates of $556.64 million. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.58 EPS. Equities research analysts expect that ICU Medical will post 3.76 EPS for the current year.

Insider Activity at ICU Medical

In related news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total value of $2,141,520.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $18,665,666.78. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $178.46, for a total value of $2,141,520.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at $18,665,666.78. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the sale, the vice president now owns 13,107 shares of the company’s stock, valued at approximately $2,139,324.54. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 40,552 shares of company stock valued at $6,679,322. 6.70% of the stock is owned by corporate insiders.

Institutional Trading of ICU Medical

A number of institutional investors have recently bought and sold shares of ICUI. Motco bought a new stake in ICU Medical in the first quarter worth $29,000. Innealta Capital LLC bought a new stake in shares of ICU Medical during the second quarter worth $32,000. GAMMA Investing LLC lifted its position in shares of ICU Medical by 75.1% during the first quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 133 shares during the last quarter. Hexagon Capital Partners LLC lifted its position in shares of ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 122 shares during the last quarter. Finally, EntryPoint Capital LLC lifted its position in shares of ICU Medical by 731.5% during the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock worth $48,000 after purchasing an additional 395 shares during the last quarter. 96.10% of the stock is currently owned by institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.